Palatin Technologies (PTN) Announces Bremelanotide Phase 3 Met co-Primary Endpoints in HSDD
Tweet Send to a Friend
Palatin Technologies, Inc. (NYSE: PTN)announced positive, statistically significant top-line results from the Reconnect Studies, its Phase 3 clinical trial program ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
